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Effect of insulinopenia and adrenal hormone deficiency on acute
potassium tolerance. The ability to dispose of an acute intra-
venous potassium load was examined in glucocorticoid-replaced
adrenalectomized rats and in rats made insulinopenic with soma-
tostatin. Adrenalectomy resulted in a significantly greater rise in
plasma potassium concentration compared with controls (1.46
0.11 vs. 0.92 0.05 mEq/liter, P <0.001) despite the excretion
of an identical percentage (47%) of the administered potassium
load in 2 hours. Somatostatin-induced insulinopenia (insulin lev-
els decreased from 37 5 to 20 3 UIm1) was also associated
with a significantly greater increment in plasma potassium con-
centration(l.5l 0.20 mEq/liter, P <0.001) compared with con-
trols, despite the excretion of a similar amount (39%) of the ad-
ministered potassium load. In animals with combined adrenal
and insulin deficiency, the rise in plasma potassium concentra-
tion occurred earlier and remained elevated for a more prolonged
period of time compared with animals with either adrenalectomy
or insulinopenia alone. Conclusion. During acute potassium
loading in the rat, insulin and adrenal hormones play an impor-
tant role in maintaining normal potassium homeostasis, primarily
by enhancing potassium uptake by extrarenal tissues.
Effet de rinsulinopénie et du deficit en hormones surrénaliennes
sur Ia tolerance aiguë au potassium. La capacité de disposer
d'une charge intraveineuse aiguë de potassium a été étudiée
chez des rats surrénalectomisés, compensés en glucocorti-
coldes, et chez des rats rendus insulinopéniques par la somatosta-
tine. La surrénalectomie a eu pour consequence une augmenta-
tion du potassium plasmatique significativement plus grande que
celle des contrôles (1,46 0,11 au lieu de 0,92 0,05 mEq/liter,P < 0,001) malgré l'excrétion en deux heures d'une fraction
identique (47%) du potassium administré. L'insulinopénie deter-
minée par la somatostatine (insulinémie diminuée de 37 5a 20
3 U/ml) était aussi associée a une augmentation signifi-
cativement plus grande de la concentration du potassium plasma-
tique (1,51 0,20 mEq/liter, P < 0,001), par comparaison aux
contrôles, malgré l'excrétion d'une fraction semblable (39%) de
Ia charge de potassium administrée. Chez les animaux ayant
a Ia fois l'insuffisance surrénale et le deficit en insuline
l'augmentation du potassium plasmatique s'installe plus tot et
dure plus longtemps que chez ceux n'ayant que l'insuffisance
surrénale de l'insulinopénie. Conclusion. Au cours de Ia charge
aiguë en potassium chez Ic rat l'insuline et les hormones surrCna-
liennes jouent un rOle important dans l'homéostasie du potas-
sium, essentiellement en augmentant la captation de potassium
par les tissues autres que le rein.
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Hyperkalemia in association with hypoaldoste-
ronism and normal or only mildly reduced renal
function has been reported with increasing frequen-
cy in patients with diabetes mellitus [1, 2]. Although
both aldosterone [3, 4] and insulin [5, 6] are known
to play important roles in overall potassium homeo-
stasis, the relative contribution of insulin versus al-
dosterone deficiency in the development of hyper-
kalemia in this syndrome has not been defined nor
has the site (renal versus extrarenal) of impaired po-
tassium tolerance been localized. Chronic adenalec-
tomy is known to result in hyperkalemia [7, 8] and a
decreased distal tubular potassium gradient [9, 10],
which can be corrected by exogenous aldosterone
[9]. Renal potassium excretion, however, may not
be the most important defense against hyperkalemia
following acute potassium loads. In human sub-
jects, less than 50% of an acute potassium load is
excreted within the 4 to 6 hours following adminis-
tration, the remainder being translocated into cells
[11]. Although aldosterone has been shown to
affect potassium uptake by rat diaphragm muscle in
vitro [12], its role in extrarenal potassium disposal
during acute potassium chloride loading in vivo has
not been systematically examined. In contrast, in-
sulin has been shown to enhance cellular uptake of
potassium both in vivo and in vitro [5, 6, 13-15], but
its effect on renal potassium excretion is less clear
[16]. Furthermore, the interaction of combined in-
sulin-aldosterone deficiency on both renal as well as
extrarenal mechanisms of acute potassium homeo-
stasis has not previously been studied.
Methods
Male Sprague-Dawley rats (Charles River Labo-
ratories, Boston, Massachusetts) were divided into
five experimental groups as described below. All
rats were maintained on 15 g of standard Purina rat
chow (total daily sodium and potassium intake
equal to 2.4 and 4.0 mEq/day, respectively) for 14
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days prior to study. At the end of this period, a 24-
hour urine sample from each rat was collected un-
der mineral oil for determination of sodium and po-
tassium excretion. On the day of study, a clearance
experiment with acute potassium chloride loading
was performed in each animal.
Group 1: Normal controls. Seventeen normal rats
underwent a clearance study (Fig. 1) with potassium
chloride loading. Each animal was anesthetized
with mactin® (Promonta, Hamburg, Germany), 12
mg/dg of body wt i.p., and a tracheostomy tube was
inserted to insure adequate ventilation. The left ca-
rotid artery and right external jugular vein were
then cannulated with PE-50 tubing for withdrawal
of blood samples and experimental infusion, respec-
tively. Transabdominal catheterization of the blad-
der was performed to allow complete collection of
urine. Surgical fluid losses were replaced with 0.15
M sodium chloride (1% body wt), following which a
constant infusion of 0.15 M sodium chloride was be-
gun and maintained at 3.3 mi/hr except during
potassium chloride administration. The GFR was
determined by the clearance of tritiated methoxy-
inulin (New England Nuclear, Boston, Massachu-
setts), which was continuously infused at 20 pCi/hr
following a priming dose of 30 pCi. Body tempera-
ture was maintained between 37 and 38° C by means
of a warming board.
After an equilibration period of 60 mm, a clear-
ance study involving six 30-mm urine collections
was carried out (Fig. 1); carotid blood samples (0.2
ml each) were withdrawn at the midpoint of each
urine collection for determination of plasma sodium
and potassium concentrations and inulin radio-
activity. During the first hour (baseline period) of
the clearance study, the maintenance 0.15 M sodium
chloride infusion was continued for the first two
urine collections. This infusion was then replaced
with an infusion of 0.121 NI potassium chloride and
0.03 M sodium chloride, also administered intra-
venously at 3.3 mi/hr to deliver 0.4 mEq of potas-
sium isotonically during the second hour (potassium
chloride period). Again two 30-mm urine samples
were collected. In the third hour (post-potassium
chloride period) the potassium chloride infusion
was replaced with the maintenance 0.15 M sodium
chloride infusion, and the final two 30-mm urine
collections were performed.
Group 2: Adrenalectomized rats. Eight rats were
bilaterally adrenalectomized 15 days prior to clear-
ance studies. On the day of adrenalectomy, each of
these rats received glucocorticoid replacement in
the form of 40 g of dexamethasone i.p. Thereafter,
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Fig. 1. Experimental protocol. Only groups 3 and 4 received the
somatostatin infusion.
replacement was 10 tg of dexamethasone each
morning until the day of the clearance study. This
daily dexamethasone dose is equivalent in glucocor-
ticoid activity to the daily corticosterone produc-
tion of the rat [17]. No mineralocorticoid replace-
ment was given. After adrenalectomy, these ani-
mals were maintained on the standard 15 g of diet as
described above and allowed free access to a 0.9%
sodium chloride and 2.5% dextrose drinking solu-
tion. The drinking bottles were weighed at the be-
ginning and end of each 24-hour collection to deter-
mine sodium intake. Clearance studies performed 2
weeks after adrenalectomy were identical to that
described for group 1 except that all adrenal-
ectomized rats received dexamethasone (50 /Lg/dg
body wt i.p.) 2 hours before surgery. This dose of
dexamethasone has been shown to have no effect
on renal electrolyte handling in the rat [18, 19].
Group 3: Somatostatin-infused normal rats.
Eight rats were treated identically to the normal
controls except for administration of somatostatin
during the potassium chloride and post-potassium
chloride periods (Fig. 1). Cyclic somatostatin (Ciba,
Summit, New Jersey) infusion was begun at 0.5 sg/
mm simultaneously with the potassium chloride in-
fusion. The somatostatin was dissolved in the ex-
perimental potassium chloride and sodium chloride
solutions so that the volume of fluid administered to
these animals was identical to that received by con-
trols.
Group 4: Somatosta tin-infused adrenalectomized
rats. Ten rats were treated identically to the adren-
alectomized (group 2) rats except for administration
of somatostatin during the potassium chloride and
post-potassium chloride periods, as described
above.
Group 5: Normal rats receiving high sodium in-
fusion. To increase urinary sodium excretion to
rates comparable to those observed in adrenal-
ectomized rats, we infused six normal rats with the
— Somatostatin infusion
(0.5 pg/mm)
0.15 M NaCI >l( 0.12 M KCI0.03 M NaCI15 M NaCI
—120 120
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maintenance 0.15 M sodium chloride solution at a
rate of 4.62 mI/hr during all periods except the po-
tassium chloride period. During the potassium chlo-
ride period, a 0.087-M potassium and 0.06-M sodium
chloride solution was infused at 4.62 mllhr to deliv-
er a total dose of 0.4 mEq of potassium. Prior to the
clearance study, these animals were treated identi-
cally to the normal controls.
In four rats from each of the five groups, arterial
pH was determined at the midpoint of the baseline,
potassium chloride, and post-potassium chloride
periods. Capillary collection tubes were sealed im-
mediately and kept on ice until the pH was mea-
sured on a microelectrode pH meter (Radiometer,
Copenhagen, Denmark). In control (group 1) and
somatostatin-infused (group 3) rats, plasma glucose
and insulin concentrations were determined during
the baseline period and at the end of the potassium
chloride period.
Analytical methods. Tritiated inulin activity was
determined in a liquid scintillation counter (Packard
Tri-Carb, Downers Grove, Illinois). Urine and
plasma sodium and potassium concentrations were
measured with a flame photometer using an internal
lithium standard (Instrumentation Laboratories,
Watertown, Massachusetts). Plasma glucose con-
centration was measured on a glucose analyzer
(Beckman Instruments, Cedar Grove, New Jersey),
and plasma insulin concentration was measured by
radioimmunoassay, with talc to separate free from
bound insulin [21].
Calculations. In the analysis of the data, urinary
excretion rates for electrolytes and values of inulin
clearance (GFR) were calculated by standard for-
mulae. The mean plasma potassium concentration
obtained during the baseline period was subtracted
from the peak plasma potassium concentration
(which occurred during the second half hour of the
potassium chloride period in every animal studied)
to determine the peak increment in plasma potas-
sium. The mean rate of potassium excretion during
the baseline period, as well as the peak rate of ex-
cretion (which also occurred during the second half
hour of the potassium chloride period in every rat),
was calculated and compared for each group. The
percentage of the potassium load excreted during
the 2 hours of the potassium chloride and post-po-
tassium chloride periods was calculated as the sum
of the mean increments in potassium excretion
above baseline in each of these two periods divided
by the administered potassium load (0.4 mEq).
The integrated area under the curve plotting the
rise in plasma potassium concentration with time
was calculated by the trapezoidal rule approxima-
tion and was carried out by computer (subroutine
QAOIAS of the Harwell Subroutine Library of the
Yale University, IBM 370/158). It is expressed as
mEq/liter X mm.
Statistical differences between groups were ana-
lyzed by the unpaired Student's t test, and the linear
regression test was used to analyze statistical corre-
lations between different parameters [22]. All data
are expressed as the means SEM.
Results
Body weights. The body weights in groups 1 to 5
were 234 8, 245 9, 223 7, 222 6, and 235
10 g, respectively.
Arterial pH. The arterial pH during the baseline
period was similar (7.39 to 7.41) in all groups, and
no change in pH occurred in any group during the
remainder of the clearance study.
Glucose and insulin levels with soinatostatin in-
fusion. In the group 1 control rats, the plasma glu-
cose and insulin concentrations (132 5 mg/dl and
45 3 U/m1) during the potassium chloride period
were similar to the baseline period (126 4 mg/dl
and 40 5 U/ml). In rats receiving somatostatin
plus potassium chloride, a 46% decline in plasma
insulin concentration from basal levels (37 5 to 20
3 jsU/ml, P <0.01) occurred, as well as a small
decrease in plasma glucose concentration (116 3
to 101 5 mg/dl; P <0.05).
Twenty-four-hour electrolyte excretion, The
mean 24-hour urinary potassium excretion of 3.71
mEq in normal animals (groups 1, 3, and 5)
was similar to the daily excretion of 3.90 0.11
mEq in adrenalectomized animals (groups 2 and 4).
No normal or adrenalectomized rat differed in its
24-hour potassium excretion by more than 20%
from its intake (4.0 mEq/day), indicating that all ani-
mals were in potassium balance.
The 24-hour urinary sodium excretion of 14.3
1.8 mEq/day in adrenalectomized rats was signifi-
cantly higher than it was in controls (2.3 0.07
mEq/day). This was due primarily to the higher so-
dium intake in adrenalectomized rats, which varied
from 10 to 21 mEq/day compared to 2.4 mEq/day in
normal controls. No normal or adrenalectomized
rat differed in its sodium excretion by more than
18% from its individually calculated intake.
Glonerular filtration rate and urinary sodium ex-
cretion (Table 1). The GFR in the adrenalectomized
groups (2 and 4), which had been maintained on a
saline drinking solution, was slightly higher during
the baseline period than it was in any of the other
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three groups (1, 3, 5) which drank only tap water.
During the potassium chloride and post-potassium
chloride period, GFR was slightly less in somatosta-
tin-infused normals (group 3) compared with con-
trols (group 1), but the difference was small (Table
I). In all groups, GFR decreased by approximately
20% during the clearance study.
Baseline urinary sodium excretion in the adrenal-
ectomized groups (groups 2 and 4) was significantly
higher than that in the control (group 1) and soma-
tostatin-infused (group 3) groups but similar to the
excretion rate found in group 5 controls rats, which
received the higher infusion rate of sodium chlo-
ride. During potassium chloride administration, the
sodium excretion rose by 10 to 30% in all groups
and then fell by about 50% during the post-potas-
sium chloride period.
Plasma potassium concentration (Table 2; Fig.
2). The mean baseline plasma potassium concentra-
tion in the two groups of adrenalectomized rats
Table 1. Glomerular filtration rate and sodium excretion rate during clearance studya
GFR UN8V
mi/mm pEqimin
Groups Baseline KC1 Post-KC1 Baseline KCI Post-KC1
1 (controls) 2.99 2.83 2.50 4.43 6.38 3.77
±0.11
2 (adrenalectomy) 3.43 3.14 2.74 9.76 10.59 5.26
3 (somatostatin) 2.91 2.36 2.09 4.40 5.60 2.63
4 (somatostatin + adrenalectomy) 3.56 3.13 2.80 9.66 11.10 5.20
5 (high sodium controls) 2.75 2.60 2.37 7.26 10.85 5.27
P values
Convs.ADX <0.01 NS NS <0.001 <0.001 <0.05
Con vs. SRIF NS <0.05 <0.02 NS NS <0.05
Con vs. SRIF + ADX <0.01 <0.05 NS <0.001 <0.001 <0.05
ADXvs. SRIF <0.02 <0.01 <0.01 <0.01 <0.01 <0.01
ADXvs.ADX+SRIF NS NS NS NS NS NS
SRIF vs. ADX + SRLF <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
High sodium con vs. con NS NS NS <0.05 <0.005 <0.05
High sodium con vs. ADX <0.001 <0.05 <0.02 NS NS NS
a All values represent the means SEM. Abbreviations are Con, controls; ADX, adrenalectomy; SRIF, somatostatin.
Table 2. Plasma potassium concentrations (PK) during clearance studiesa
Peak increment
Baseline PK Peak P potassium Post-KCI P5
Groups mEqiliter mEq/liter mEq/iiter mEqiliter
1 (controls) 4.02 4.95 0.92 4.19
±0.05
2 (adrenalectomy) 4.35 5.81 1.46 4.95
3 (somatostatin) 4.09 5.60 1.51 4.60
4 (somatostatin + adrenalectomy) 4.56 6.21 1.66 5.55
5 (highsodiumcontrols) 3.95 4.98 1.03 4.33
P values
Con vs. ADX <0.001 <0.001 <0.001 <0.001
Con vs. SRIF NS <0.005 <0.001 <0.001
Con vs. SRIF + ADX <0.005 <0.001 <0.001 <0.001
ADXvs. SRIF <0.05 NS NS NS
ADX vs. ADX + SRIF NS NS NS <0.05
SRIFvs.ADX+SRIF <0.01 <0.05 NS <0.001
High sodium con vs. con NS NS NS NS
Highsodiumconvs.ADX <0.001 <0.001 <0.001 <0.001
a All values represent the means SEM. Abbreviations are defined in Table 1.
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(groups 2 and 4), 4.42 0.09 mEq/liter, was slightly
but significantly higher (P < 0.001) than that in
group 1 control rats (4.02 0.05 mEq/liter). Base-
line plasma potassium concentration in somatosta-
tin-infused rats (group 3) and in rats receiving the
higher infusion rate of sodium chloride (group 5)
was similar to control rats.
Following potassium chloride infusion, plasma
potassium rose to peak value of 5.81 0.14 mEqI
liter in the adrenalectomized rats (group 2) com-
pared to 4.95 0.07 mEq/liter in the group 1 con-
trols (P <0.001). The peak increment in plasma po-
tassium concentration was 1.46 0.11 mEq/liter in
this adrenalectomized group versus 0.92 0.05
mEq/liter in the control group (P <0.001; Fig. 2).
During the post-potassium chloride period, the
plasma potassium concentration in these adrenal-
ectomized rats, 4.95 0.08 mEq/liter, remained sig-
nificantly higher than it was in controls, 4.19 0.06
mEq/liter (P <0.001). In addition, the incremental
area in plasma potassium concentration above base-
line was significantly higher in adrenalectomized
rats (91.5 6.2 mEq/liter x mm) compared to con-
trols (53.2 3.7 mEq/liter X mm; P < 0.001).
Infusion of somatostatin with potassium chloride
into normal rats (group 3) resulted in a significant
increase in both the peak plasma potassium concen-
tration, 5.60 0.18 mEq/liter, and the peak in-
crement in plasma potassium concentration above
baseline, 1.51 0.20 mEq/liter (Fig. 2), compared
with control rats receiving potassium chloride alone
(P <0.001). The peak increase in plasma potassium
concentration in somatostatin-infused rats, as well
as the incremental area in plasma potassium con-
centration above baseline (92.2 9.9 mEq/liter X
mm; P <0.005 compared with controls), was simi-
lar to that observed in adrenalectomized animals re-
ceiving potassium chloride without somatostatin.
When potassium chloride plus somatostatin was
infused into adrenalectomized rats (group 4), the in-
crements in plasma potassium concentration above
basal during the first 30 mm of potassium chloride
and during the entire post-potassium chloride peri-
od was significantly higher (P < 0.05) compared
with the rise in either the adrenalectomized rats
(group 2) or the somatostatin-infused rats (group 3;
Fig. 2). The peak increment in plasma potassium
concentration in somatostatin-infused adrenal-
ectomized rats, 1.66 0.07 mEq/liter (Fig. 2), tend-
ed to be higher than it was with either somatostatin
or adrenalectomy alone. The integrated area for the
rise in plasma potassium concentration above base-
line was significantly higher in animals with corn-
Time, rn/n
Fig. 2. The increment in plasma potassium Concentration above
baseline in control (._s), somatostatin-infused (O--O), adrenal-
ectomized (o. . ..o), and adrenalectomized rats receiving soma-
tostatin (•——•). The potassium chloride (0.4 mEq) was in-
fused from 0 to 60 mm. All values represent the mean SEM.
One asterisk(*) indicates P <0.05. Two asterisks (**) indicate P
<0.005 compared with the value in control rats.
bined deficiency(1l8.6 4.2 mEq/liter x mm) com-
pared to animals with either adrenalectomy alone
(91.5 6.2 mEq/liter X mm; P < 0.005) or in-
sulinopenia alone (92.2 9.9 mEq/liter X mm; P <
0.05).
The plasma potassium concentration in the high-
sodium-infusion normal rats (group 5) was similar to
that in the normal controls at every point in the
clearance study and was consistently less than that
of the adrenalectomized animals (P < 0.01).
Urinary potassium excretion (Table 3). Baseline
and peak urinary potassium excretion rates, as well
as the percent of the potassium load excreted in 2
hours (39 to 52%), were similar in all groups. Of par-
ticular note is that the potassium excretion rate, as
well as the percent of potassium chloride load ex-
creted in adrenalectomized rats (group 2) was simi-
lar to that in controls.
A significant correlation (P < 0.01) between uri-
nary potassium excretion and plasma potassium
concentration was observed in all groups except in
group 4 where considerable scatter of the points ex-
E
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isted. The slope of the regression line relating uri-
nary potassium excretion to plasma potassium con-
centration in group 2 adrenalectomized rats (1.32
0.43) tended to be less than that found in group 5
rats (2.42 0.68) despite similar high rates of so-
dium excretion, but this difference did not reach
statistical significance. The slope of the line in
group 3 somatostatin-infused rats (1.55 0.34) was
similar to that found in group 1 control rats (1.64
0.33).
Plasma potassium increment per amount of po-
tassium retained (Fig. 3). To factor for small varia-
tions in urinary potassium excretion between
groups, we factored the integrated rise in plasma
potassium concentration above baseline in each rat
by the amount of potassium retained by that rat.
This expression provides an index of extrarenal po-
tassium tolerance in each animal. The integrated
rise in plasma potassium concentration was ob-
tained by determining the area under the curve of
the rise in plasma potassium concentration with
time. The rise in plasma potassium concentration
per amount of potassium retained was significantly
higher (P < 0.005) in adrenalectomized rats (418
mm/liter) and insulinopenic rats (408 67 min/
liter) compared to control animals (231 25 minI
liter) (Fig. 3). When combined insulin and adrenal
insufficiency was created, the delta plasma potas-
sium concentration per amount of potassium re-
tained (624 59 mm/liter) was again higher (P <
0.001) than it was in control animals and was also
higher (P < 0.05) than the value obtained in animals
receiving either adrenalectomy alone or in-
sulinopenia alone.
Discussion
The present study demonstrates that both adrenal
hormones and insulin play important roles in the
disposal of an acute potassium load and that a major
site of their action is exerted on extrarenal tissues to
enhance cellular uptake of potassium. In chronical-
ly adrenalectomized rats and in rats made in-
sulinopenic with somatostatin, the increment in
plasma potassium concentration following intra-
venous potassium chloride administration was high-
er than it was in control animals, despite a urinary
potassium excretion rate that was similar to con-
trols.
The role of aldosterone in the renal contribution
to chronic potassium homeostasis is well estab-
lished [8, 20]. Its ability to augment renal potassium
excretion during acute potassium chloride loading,
however, is less certain [23]. Alexander and Levin-
sky [24] suggested an extrarenal role for aldoste-
rone in acute potassium homeostasis. In their stud-
ies, rats preconditioned with a high-potassium diet
displayed enhanced potassium tolerance to an acute
potassium chloride load compared with controls fed
a normal diet. This effect could be demonstrated
both in the presence and absence of kidneys, could
be abolished by adrenalectomy, and could be simu-
lated by high (but now low) doses of mineralo-
corticoid. An extrarenal effect of aldosterone in
vitro has also been demonstrated by Adler [12] and
Lim and Webster [25] using the rat hemidiaphragm
preparation.
The present results lend further support to the
concept that aldosterone exerts a major effect on
extrarenal potassium disposal following acute po-
Table 3. Urinary potassium excretion (UKV) during clearance studiesa
Groups
UKV
p.Eq/rnin Potassium load
excreted
%Baseline Peak Post-KCI
I (controls) 2.06 0.14 5.19 0.12 2.82 0.12 47.3 6
2 (adrenalectomy) 2.37 0.22 5.53 0.22 3.39 0.11 47 5
3 (somatostatin) 2.29 0.14 5.04 0.30 2.98 0.24 39 5
4 (somatostatin > adrenalectomy) 2.45 0.26 5.54 0.27 3.52 0.20 52 5
5 (highsodiumcontrols) 2.05 0.18 4.92 0.24
P values
2.80 0.27 42 7
Convs.ADX NS NS <0.005 NS
Convs.SRIF NS NS NS NS
Con vs. SRIF + ADX NS NS <0.01 NS
ADXvs.SRIF NS NS NS NS
ADXvs.ADX+SRIF NS NS NS NS
SRIFvs.ADX+SRIF NS NS NS NS
High sodium con vs. con NS NS NS NS
High sodium con vs. ADX NS NS NS NS
a All values represent the means SEM. Abbreviations are defined in Table I.
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tassium chloride administration. Despite the excre-
tion of an identical percentage (47%) of the adminis-
tered potassium load in both control and adrenal-
ectomized rats, the increment in plasma potassium
concentration was significantly greater in adrenal-
ectomized rats. Thus, the decreased potassium to!-
erance in adrenalectomized rats must be attributed
to impaired tissue uptake of potassium. Whether
the defect is the result of aldosterone deficiency or
is due to a deficiency of some other adrenal hor-
mone is not answered by the present study. It is
known that adrenalectomy in rats reduces the
amount of circulating epinephrine to very low levels
[26], whereas norepinephrine levels remain relative-
ly normal. It is also known that beta agonists can
enhance cellular uptake of potassium [27, 28] by
liver and skeletal muscle [28]. More recently, Lum
and Lockwood [29, 30] have shown that epineph-
rine and other beta agonists (but not alpha agonists)
exert a protective effect against hyperkalemia in
cats infused simultaneously with potassium chlo-
ride. The protective effect of epinephrine was not
altered by prior nephrectomy or pancreatectomy,
indicating that this effect was not dependent on re-
nal potassium excretion or the presence of insulin.
Thus, the current findings could also be explained
by a deficiency of epinephrine. Because all animals
received physiologic replacement doses of dexa-
methasone, it is unlikely that insufficient glucocorti-
coid replacement can explain the persistent defect
in potassium metabolism. In addition, the impair-
ment in cellular uptake of potassium could not be
attributed to acidosis in adrenalectomized animals,
because blood pH was similar to controls and did
not change during the study. Last, although consid-
erable controversy exists concerning the actual in-
tracellular potassium content of adrenalectomized
animals [17, 31], it is conceivable that the extrarenal
defect was caused, in part, by an elevation in tissue
potassium content in the adrenalectomized rats.
Although the inability to dispose of an acute po-
tassium load in adrenalectomized rats appears to be
due mainly to an extrarenal defect, the data also
suggest that adrenalectomized rats may have a
subtle impairment in renal potassium excretion.
Thus, although the adrenalectomized rats were in
potassium balance prior to the clearance study (24-
hour urinary potassium excretion = dietary intake)
and displayed baseline potassium excretion rates
that were similar to those of control animals, this
level of potassium excretion was achieved at the ex-
pense of a slightly, but significantly elevated base-
line plasma potassium concentration. This observa-
tion is consistent with a mild defect in chronic renal
potassium homeostasis in the adrenalectomized
rats. Previous studies have shown that urinary po-
tassium excretion varies directly with the plasma
potassium concentration during potassium loading
[32]. The present study demonstrates that this di-
rect relationship is present even in adrenal-
ectomized rats that have been totally depleted of
mineralocorticoid activity. The slope of the line re-
lating urinary potassium excretion to plasma potas-
sium concentration in adrenalectomized rats tended
to be less, however, than it was in controls (group
5), which had a similar rate of sodium excretion.
These data are compatible with but do not conclu-
sively document a defect in renal potassium excre-
tion following acute potassium loading in adrenal-
ectomized rats. It is unlikely that this apparent de-
fect in renal potassium excretion, present in
adrenalectomized rats, can be explained by a fall in
GFR during the study, because GFR was reduced
to a similar extent (14 to 21%) in all groups. Further-
more, it is well known that urinary potassium excre-
tion is relatively independent of GFR [33].
Results from previous studies clearly demon-
strate an impairment in potassium homeostasis fol-
lowing adrenalectomy in all species examined [7, 8,
20, 36, 37]. The site of the defect (renal vs. extra-
renal), however, has not been clearly delineated. In
studies where decreased renal potassium excretion
has been demonstrated in adrenalectomized ani-
1**
Control ADX Somat. ADXSomat.
Fig. 3. The rise in plasma potassium concentration per amount
ofpotassium retained in control animals, adrenalectomized rats
(ADX,), insulinopenic rats (Son',at), and rats with combined in-
sulinopenia and adrena/ectomy (ADX-Somat). All values repre-
sent the mean SEM. Two asterisks (**) indicate P <0.005 com-
pared with the value in control rats.
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mals [8, 20], the animals were frequently not re-
placed with volume or glucocorticoids and the
blood pH was not monitored. It is possible that
changes in systemic and/or renal hemodynamics
secondary to volume contraction could have con-
tributed to the defect in potassium excretion. In
contrast, the current findings indicate that, in gluco-
corticoid and volume-replaced adrenalectomized
rats, the inability to dispose of an acute potassium
load is primarily due to an extrarenal defect result-
ing from an absence of aldosterone or some other
adrenal hormone.
Following somatostatin-induced insulinopenia, a
significant decline in acute potassium tolerance was
also observed, despite the renal potassium excre-
tion that was similar to control rats. These findings
suggest that somatostatin administration, like adre-
nalectomy, is associated principally with an impair-
ment in the extrarenal mechanisms of cellular po-
tassium uptake. Previous results from our laborato-
ry have demonstrated that somatostatin induces a
similar impairment in acute potassium tolerance in
dogs [.5] and that this can be corrected by replace-
ment of basal insulin levels alone. Thus, the defect
in potassium tolerance following somatostatin has
been shown to be secondary to the resultant in-
sulinopenia. No significant defect in renal potas-
sium excretion was observed in insulinopenic rats.
When the increase in urinary potassium excretion
was related to the increase in plasma potassium
concentration, the slope of the line in somatostatin-
infused animals (1.55 0.34) was similar to controls
(1.64 0.33). These results suggest that insulin has
no direct effect on renal tubular potassium secretion
and that the changes in urinary potassium excretion
following somatostatin-induced insulinopenia and
exogenous insulin administration [16] are the con-
sequence of changes in plasma potassium concen-
tration brought about by insulin's action on extra-
renal tissues.
When somatostatin was infused into adrenal-
ectomized rats to bring about combined insulin and
adrenal hormonal deficiency, the defect in potas-
sium tolerance was greater than it was with either
somatostatin or adrenalectomy alone (Fig. 2). The
rise in plasma potassium occurred earlier and re-
mained elevated for a more prolonged period of
time, resulting in an integrated rise in plasma potas-
sium concentration above basal that was signifi-
cantly higher in these animals with combined defi-
ciency compared to those with either insulin or
adrenal insufficiency alone. Renal potassium ex-
cretion in this group (group 4), as well as the per-
cent of the administered potassium excreted within
2 hours, was similar to control rats.
Statistical differences in potassium tolerance be-
tween animals with adrenal or insulin insufficiency
alone compared with those with combined defi-
ciency were also demonstrated when the incremen-
tal rise in plasma potassium concentration above
baseline was factored by the amount of potassium
retained. This expression yields a more specific in-
dex of extrarenal potassium tolerance. As can be
seen in Fig. 3, the defect in extrarenal potassium
tolerance was similar in adrenalectomized and in-
sulinopenic rats, both groups exhibiting a signifi-
cantly greater rise (P < 0.005) in plasma potassium
per amount of potassium retained compared to con-
trol rats. The greatest rise in plasma potassium con-
centration per amount of potassium retained oc-
curred in animals with combined adrenal and insulin
insufficiency where the rise was significantly greater
than that occurring in animals with either adrenal-
ectomy alone or insulinopenia alone. Thus, the
combined effects of adrenal and insulin deficiency
produce a degree of extrarenal potassium intoler-
ance that is greater than that occurring with either
adrenal or insulin deficiency alone.
The combined effects of insulinopenia and adre-
nal hormone deficiency in producing impaired cellu-
lar potassium uptake may have particular clinical
relevance because hypoaldosteronism is known to
occur with increased frequency in diabetic subjects
[1, 2] and the combination may lead to potentially
fatal hyperkalemia [34]. Only one previous study
has examined the ability of diabetic subjects with
hypoaldosteronism to dispose of an acute potas-
sium load [35]. Although these diabetics demon-
strated a slight decrease in renal potassium excre-
tion compared with controls, the difference was not
statistically significant and the rise in plasma potas-
sium concentration following acute potassium load-
ing could not be explained by the marginal renal de-
fect. These results are consistent with the present
findings and suggest that a large part of the hyper-
kalemia in diabetics with hypoaldosteronism is due
to a defect in extrarenal potassium homeostasis.
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